Cell&Gene

[Cell&Gene @_CellandGene]

#CellAndGenePodcast is brought to you by @_CellandGene in partnership with @AppliedBio. Check out the latest episode featuring @ShorelineBio CSO, Robert Hollingsworth PhD. #macrophage #cancer

https://t.co/83lBSaaqpv

[Cell&Gene @_CellandGene]

To advance the field of immuno-oncology, we must shift our mindsets and ways of working to embrace agile practices and new levels of knowledge sharing – both within and between organizations.

By Peter Sandor, @AstellasUS

https://t.co/gHvO53Nmul

[Cell&Gene @_CellandGene]

Anna Rose Welch shares a few of the actionable takeaways she walked away with from the ARM/ASGCT potency assay working session in the hopes they will be a complementary exploration of the analytical challenge impacting every ATMP company.

https://t.co/XpCl6aH77C

[Cell&Gene @_CellandGene]

While this list includes some of my favorite editorial from 2022, it’s not even close to being as extensive as I’d like. Why is that? Our library of content is so deep and so rich, I couldn’t possibly share and recap all of it with you in one article.

https://t.co/WTAZo1kz5n

[Cell&Gene @_CellandGene]

A judge ruled #stemcells removed from a patient, centrifuged, & reinjected into a patient are not drugs & do not require FDA premarket approval. FDA filed an appeal but until it's heard the decision may have consequences for stem cell therapy companies.

https://t.co/iGdZy13w8X

[Cell&Gene @_CellandGene]

Here, I offer my biggest takeaways from a recent ARM/ASGCT workshop on one of the most popular topics to gossip about both in and outside the analytical labs: Potency assays.

https://t.co/PA1l1WNwbh

[Cell&Gene @_CellandGene]

Knowledge of the applicable rules, legal challenges, & ways to ensure the enforcement of proprietary rights requires companies to invest in negotiating and drafting robust & balanced #CDMO #ServiceAgreements.
#pharmaceuticaloutsourcing #drugmanufacturing

https://t.co/8zJlwOgBbO

[Cell&Gene @_CellandGene]

Leveraging human genetics data early in the drug discovery process to inform target prioritization is a powerful approach to mitigate risk and increase the likelihood of advancing safe therapies that transform patient’s lives.

By Vor Bio

https://t.co/oJfUpaoIn5

[Cell&Gene @_CellandGene]

#CellAndGenePodcast is brought to you by @_CellandGene in partnership with @AppliedBio. Check out the latest episode featuring @ShorelineBio CSO, Robert Hollingsworth PhD. #macrophage #cancer

https://t.co/83lBSaaqpv

[Cell&Gene @_CellandGene]

In the final part of the series, experts from @KitePharma, @NovartisGene, and @SwanBioTx explain how to drive down #COGS and expedite commercial-scale manufacturing in the #CGT space.

https://t.co/bsIVROLhmN

[Cell&Gene @_CellandGene]

To advance the field of immuno-oncology, we must shift our mindsets and ways of working to embrace agile practices and new levels of knowledge sharing – both within and between organizations.

By Peter Sandor, @AstellasUS

https://t.co/gHvO53Nmul

[Cell&Gene @_CellandGene]

Anna Rose Welch shares a few of the actionable takeaways she walked away with from the ARM/ASGCT potency assay working session in the hopes they will be a complementary exploration of the analytical challenge impacting every ATMP company.

https://t.co/XpCl6aH77C

[Cell&Gene @_CellandGene]

While this list includes some of my favorite editorial from 2022, it’s not even close to being as extensive as I’d like. Why is that? Our library of content is so deep and so rich, I couldn’t possibly share and recap all of it with you in one article.

https://t.co/WTAZo1kz5n

[Cell&Gene @_CellandGene]

A judge ruled #stemcells removed from a patient, centrifuged, & reinjected into a patient are not drugs & do not require FDA premarket approval. FDA filed an appeal but until it's heard the decision may have consequences for stem cell therapy companies.

https://t.co/iGdZy13w8X

[Cell&Gene @_CellandGene]

In part one of this two-part series, as seen in Life Science Leader, experts from Kite Pharma, Novartis Gene Therapies, and SwanBio Therapeutics weigh in on understanding how to drive down COGS and expedite commercial-scale manufacturing in the CGT space.

https://t.co/sj88yZKgPU

[Cell&Gene @_CellandGene]

To figure out what the future holds for companies in the RNA sector of the ATMP space, I sat down with four executives to discuss their expectations. As you’ll note, there is no shortage of work facing the RNA therapeutics industry in the year(s) ahead.

https://t.co/bzy68jzKrz

[Cell&Gene @_CellandGene]

Knowledge of the applicable rules, legal challenges, & ways to ensure the enforcement of proprietary rights requires companies to invest in negotiating and drafting robust & balanced #CDMO #ServiceAgreements.
#pharmaceuticaloutsourcing #drugmanufacturing

https://t.co/8zJlwOgBbO

[Cell&Gene @_CellandGene]

Here, I offer my biggest takeaways from a recent ARM/ASGCT workshop on one of the most popular topics to gossip about both in and outside the analytical labs: Potency assays.

https://t.co/PA1l1WNwbh

[Cell&Gene @_CellandGene]

Leveraging human genetics data early in the drug discovery process to inform target prioritization is a powerful approach to mitigate risk and increase the likelihood of advancing safe therapies that transform patient’s lives.

By Vor Bio

https://t.co/oJfUpaoIn5

[Cell&Gene @_CellandGene]

#CellAndGenePodcast is brought to you by @_CellandGene in partnership with @AppliedBio. Check out the latest episode featuring @ShorelineBio CSO, Robert Hollingsworth PhD. #macrophage #cancer

https://t.co/83lBSaaqpv